Nutraceuticals CDMO Market Size & Growth Forecast 2026–2035, By Segments (Services, Dosage Form, Company Size), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Nutraceuticals CDMO Market size was valued at USD 45.21 Billion in 2025 and is projected to grow at a 7.7% CAGR from 2026 to 2035, crossing USD 94.93 Billion by 2035. The industry revenue for 2026 is estimated at USD 48.26 billion.

• Base Year Value (2025): USD 45.21 Billion
• CAGR (2026-2035): 7.7%
• Forecast Year Value (2035): USD 94.93 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Nutraceuticals CDMO Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 39.33% share in 2025, supported by a mature outsourcing ecosystem, established supplement brands, and integrated CDMO capabilities spanning formulation through commercial production.
  • Asia Pacific is forecast to grow at an 8.7% CAGR, fueled by expanding contract manufacturing, cost-effective production, scalable ingredient sourcing, and increasing outsourcing by regional and international brands.

• Segment Momentum:

  • Manufacturing and Packaging held a 33.92% share in 2025 because brands rely on CDMOs for commercial-scale production, validated processes, accurate labeling, and shelf-ready packaging that supports efficient product launches.
  • Softgel is the fastest-growing dosage form as brands increasingly develop products containing oils and sensitive ingredients that require specialized processing, improved stability, and enhanced consumer appeal.

• Market Expansion Drivers:

  • Rising outsourcing of nutraceutical production by SMEs and pharma companies.
  • Growing consumer demand for immunity, wellness, and preventive healthcare supplements.
  • Adoption of advanced manufacturing technologies like AI, RPA, and 3D printing.

• Leading Market Participants:

  Prominent players in the nutraceuticals CDMO market include Catalent, Inc. (United States), Lonza Group AG (Switzerland), Aenova Group GmbH (Germany), NutraScience Labs, Inc. (United States), Robinson Pharma, Inc. (United States), Health Wright Products, Inc. (United States), INPHARMA S.p.A. (Italy), Innovations in Nutrition + Wellness, Inc. (United States), NutraPak USA, LLC (United States), Sirio Pharma Co., Ltd. (China).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 45.21 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 94.93 Billion by 2035
  • Growth Forecasts: 7.7% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Manufacturing and Packaging (Services) | Tablets & Capsules (Dosage Form) | Large Companies (Company Size)
  • Emerging Opportunity Segment: Product Formulation and Development (Services) | Softgel (Dosage Form) | Mid-Sized Companies (Company Size)

Market Growth Drivers and Industry Trends

Rising outsourcing of nutraceutical production by SMEs and pharma companies

As smaller nutraceutical brands push into new formulations and larger pharmaceutical companies extend into consumer health, outsourcing has become a practical route to launch products without committing capital to dedicated facilities, regulatory systems, and specialized formulation teams. This is strengthening development in the nutraceuticals CDMO market because clients increasingly rely on external partners for end-to-end capabilities such as ingredient sourcing, dosage form design, pilot batches, scale-up, quality documentation, and packaging. For SMEs, the appeal is speed and lower fixed-cost exposure; for pharma companies, it is access to established nutraceutical manufacturing know-how and flexible capacity that fits shorter product cycles and fragmented product portfolios.

Growing consumer demand for immunity, wellness, and preventive healthcare supplements

Stronger consumer interest in daily health management is pushing brand owners to expand supplement portfolios faster and refresh formulations more often, especially in categories tied to immunity support, gut health, healthy aging, and general wellness. That behavior is driving demand for the nutraceuticals CDMO market because manufacturers are being asked to convert market trends into scalable products with acceptable taste, stability, bioavailability, and shelf life across formats such as gummies, powders, capsules, and functional beverages. As preventive healthcare purchasing becomes more routine, CDMOs gain a larger role in helping brands shorten development timelines and respond to shifts in ingredient preference, label claims, and delivery formats.

Adoption of advanced manufacturing technologies like AI, RPA, and 3D printing

Technology adoption is reshaping how CDMOs compete by improving precision, speed, and operating flexibility in formulation and production. In the nutraceuticals CDMO market, AI supports faster formulation optimization and demand planning, while robotic process automation reduces manual bottlenecks in documentation, compliance workflows, and batch handling; 3D printing opens new possibilities for customized dosage forms and small-run development work. These capabilities influence client selection because brand owners increasingly favor partners that can reduce development errors, handle complex product specifications efficiently, and support differentiated offerings without slowing commercialization.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Growing nutraceutical industry and CDMO adoption	2.50%	Short term (≤ 2 yrs)	North America, Europe	Medium	Fast
Technological innovations in nutraceutical formulations	2.60%	Medium term (2–5 yrs)	North America, Asia Pacific	Low	Moderate
Expansion of nutraceutical manufacturing in emerging markets	2.60%	Long term (5+ yrs)	Asia Pacific, Latin America	Low	Slow
Rising outsourcing of nutraceutical production by SMEs and pharma companies	2.10%	Moderate	North America, Asia Pacific	High	Near Term
Growing consumer demand for immunity, wellness, and preventive healthcare supplements	2.30%	High	Global	High	Near Term
Adoption of advanced manufacturing technologies like AI, RPA, and 3D printing	1.60%	Moderate	North America, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading position in 2025, accounting for a 39.33% share of the nutraceuticals CDMO market. Its leadership is supported by a mature outsourcing environment, established supplement and functional wellness brands, and a strong base of contract development and manufacturing providers that can manage formulation, regulatory documentation, scale-up, and commercial production within integrated operating models. In practice, this allows brand owners to move products from concept to launch with greater speed and consistency, while maintaining quality and compliance requirements that are critical in a tightly specified consumer health category.

Asia Pacific is projected to expand at an 8.7% CAGR over the forecast period, driven by increasing contract manufacturing adoption among regional nutraceutical brands and the ongoing buildout of production capabilities across key manufacturing hubs. Growth in the nutraceuticals CDMO market is being fueled by the region’s ability to support cost-effective production, flexible batch manufacturing, and ingredient sourcing at scale, which makes it attractive both for domestic companies and for international firms seeking external manufacturing partners. As outsourcing activity deepens, CDMOs in the region are seeing stronger demand for end-to-end services that align with faster product cycles and broader portfolio expansion.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Developing
Cost-Sensitive Region	Low	High	Medium	High	High
Regulatory Environment	Supportive	Neutral	Supportive	Neutral	Neutral
Demand Drivers	Strong	Strong	Strong	Moderate	Moderate
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	High	High	Medium	Medium
New Entrants / Startups	Dense	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Strong	Stable	Stable	Stable

Key Country Insights

United States

Contract Innovation Hub

The U.S. nutraceuticals CDMO market is shaped by strong demand for outsourced formulation, clinical-grade production, and rapid product commercialization. U.S. companies prioritize scalable manufacturing, clean-label ingredient integration, and end-to-end development services to support fast-growing wellness brands.

Japan

Advanced Functional Nutrition

Japan emphasizes sophisticated nutraceutical CDMO capabilities supporting functional foods and clinically oriented supplements. Japan prioritizes high-purity formulations, innovation in bioavailable ingredients, and strong alignment with aging population health needs.

South Korea

Wellness Manufacturing Scale-Up

South Korea’s nutraceuticals CDMO market is driven by expanding health supplement brands requiring agile manufacturing and product diversification. South Korea prioritizes rapid formulation cycles, cosmetic-nutrition convergence, and export-oriented production capabilities.

Germany

Quality-Driven Formulation

Germany focuses on high-compliance nutraceutical CDMO services with emphasis on precision formulation and stringent quality standards. The Germany market prioritizes scientifically validated ingredients, regulated production environments, and contract manufacturing partnerships aligned with EU health regulations.

France

Premium Nutritional Science

France focuses on nutraceutical CDMO services centered on scientifically backed formulations and premium health products. France prioritizes ingredient traceability, regulatory compliance, and contract manufacturing for high-value dietary supplements.

Italy

Mediterranean Wellness Formulation

Italy emphasizes nutraceutical CDMO development rooted in natural ingredient sourcing and Mediterranean health positioning. Italy prioritizes formulation authenticity, functional ingredient integration, and flexible production for nutraceutical brands.

Segment Leadership and Growth Trends

  Services Segment Analysis: Manufacturing and Packaging (Largest Segment) vs Product Formulation and Development (Fastest-Growing Segment)

Within the nutraceuticals CDMO market, Manufacturing and Packaging held the leading position in 2025 with a 33.92% share. Its leadership is maintained through the fact that commercial-scale production and final-pack execution are the most operationally intensive parts of the outsourcing chain, requiring validated processes, capacity reliability, and packaging formats that meet retail, e-commerce, and regulatory expectations. Brand owners often rely on CDMO partners most heavily at this stage because efficient batch production, labeling accuracy, and shelf-ready presentation have direct effects on speed to market and product consistency.

Product Formulation and Development is emerging as the fastest-growing service area in the nutraceuticals CDMO market as brands increasingly seek differentiated products rather than standard contract output. Growth is being aided by rising demand for customized blends, bioavailability optimization, taste masking, and dosage innovation that can help new launches stand out in a crowded supplement environment. Compared with routine manufacturing services, formulation and development gains stronger momentum because it sits earlier in the value chain and shapes the product concept, performance profile, and manufacturability before scale-up begins.

Dosage Form Segment Analysis: Tablets & Capsules (Largest Segment) vs Softgel (Fastest-Growing Segment)

By 2025, Tablets & Capsules accounted for the largest share within the nutraceuticals CDMO market dosage form segment. Their continued leadership reflects established consumer familiarity, broad ingredient compatibility, efficient high-volume production, and easier handling across packaging and distribution channels. In the nutraceuticals CDMO market, these formats remain the default choice for many supplement brands because they balance cost control, dosing precision, and manufacturing scalability better than many alternative dosage forms.

Softgel is the fastest-growing dosage form in the nutraceuticals CDMO market, gaining momentum as brands expand offerings that require improved delivery for oils, lipid-based actives, and sensitive ingredients. Its growth relative to tablets and capsules is driven by practical formulation needs, especially where ingredient stability, swallowability, and consumer appeal are central to product design. As nutraceutical companies pursue more specialized formulations, softgel outsourcing is rising because it demands dedicated processing expertise and production capabilities that many brands do not maintain in-house.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Services	Product Formulation and Development, Manufacturing and Packaging, Research & Development (R&D), Regulatory Compliance, Others	Manufacturing and Packaging	Product Formulation and Development
Dosage Form	Tablets & Capsules, Powder, Softgel, Others	Tablets & Capsules	Softgel
Company Size	Small Companies, Mid-Sized Companies, Large Companies	Large Companies	Mid-Sized Companies

Competitive Landscape and Market Positioning

Leading companies in the nutraceuticals CDMO market:

1. Catalent Inc. (United States)

2. Lonza Group AG (Switzerland)

3. Aenova Group GmbH (Germany)

4. NutraScience Labs Inc. (United States)

5. Robinson Pharma Inc. (United States)

6. Health Wright Products Inc. (United States)

7. INPHARMA S.p.A. (Italy)

8. Innovations in Nutrition + Wellness Inc. (United States)

9. NutraPak USA LLC (United States)

10. Sirio Pharma Co. Ltd. (China)

The nutraceuticals CDMO market is expanding as outsourcing demand for formulation and manufacturing services increases. Innovation is driven by customized product development and efficiency in production processes. The nutraceuticals CDMO market continues to grow with rising demand for functional health products.

Industry Development/News

Company Name	Date	Key Development
Tirupati Medicare	Mar-25	Tirupati Medicare secured a ₹1,000 crore investment from Kotak, enabling a full exit of its existing investor and supporting the company’s expansion strategy in the nutraceuticals CDMO sector. The capital infusion is positioned to accelerate inorganic growth initiatives, strengthening operational scale and competitive positioning within contract development and manufacturing services for nutraceutical products.
Lonza	Oct-20	Lonza invested USD 93 million in its capsule and health ingredient division to expand softgel manufacturing capacity across eight global facilities. The initiative strengthens its production footprint in health ingredient manufacturing and enhances its ability to meet rising demand in nutraceutical CDMO and related delivery systems for dietary supplements and functional health products.
Lonza	Feb-23	Lonza expanded its bioconjugation facility in Visp, Switzerland, reinforcing its advanced manufacturing capabilities in complex biologics and health ingredient production. The expansion supports increased production capacity and strengthens its position in high-value CDMO services relevant to nutraceutical and health science applications requiring specialized bioconjugation expertise.